IL13RA2 and neoplasm: In one subject, IL-13Rα2-targeted CAR T treatment altered the tumor microenvironment (TME) by activating the host immune system to target the tumor through enhanced IFN-γ signaling after CAR treatment, which subsequently resulted in subsequential complete response in the subject [101].